by Elizabeth Tolchin A novel combination of a tumor suppressor with a growth factor inhibitor is yielding promising results for breast cancer.
by Elizabeth Tolchin In a pharmacogenomic study, researchers found a genetic marker related to immune response for Stevens-Johnson syndrome (SJS), a life-threatening skin condition brought about by an adverse reaction to certain medications.
by Elizabeth Tolchin By using past experience from the study of fusion-inhibitory peptides in HIV, researchers found a similar inhibitory mechanism for severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV).
by Elizabeth Tolchin A contract research organization was granted a patent this week that covers the use of zebrafish ( Danio rerio ) for drug screening using microliter plates.
by Elizabeth Tolchin By developing a novel antibody drug discovery technology, researchers from Texas Tech University, Amarillo, Texas, spawned a start-up firm, now six weeks young. Venture capital firm Emergent Technologies Inc., Austin, Texas, licensed the technology from the university and formed the start-up, Receptor Logic Ltd.
by Elizabeth Tolchin The FDA approved a new cancer treatment candidate by Genentech Inc., South San Francisco, called Avastin, this February. A recombinant humanized antibody to vascular endothelial growth factor (VEGF), the drug is designed to bind to and inhibit VEGF, a protein that plays a role in tumor angiogenesis.
by Elizabeth Tolchin In support of the US Food and Drug Administration (FDA) initiative on the use of pharmacogenomic data in the drug submission process, Iconix Pharmaceuticals Inc. is releasing a set of its proprietary Drug Signature genomic biomarkers to the scientific community for research and validation.
by Elizabeth Tolchin A structure-guided drug discovery company is using software that allows their bench chemists to handle library design and enumeration. Optive Research Inc., recently deployed the software, called Benchware, for Structural GenomiX (SGX).
by Elizabeth Tolchin Researchers involved in comparative studies of bacterial genomes devised an application of microarray technology in which whole genomes are arrayed on a single glass slide and probed for the presence or absence of specific genes or alleles.
by Elizabeth Tolchin Researchers at the European Molecular Biology Laboratory (EMBL) and the German Cancer Research Centre (DKFZ), both based in Heidelberg, Germany, have a new Chemical Genomics Facility to call their own. It is one of the first academic facilities for small-molecule screening in Europe.
by Elizabeth Tolchin A new quantitative polymerase chain reaction (qPCR) assay, called BD Qzyme, from BD Biosciences Clontech, allows researchers to more easily quantify multiple target genes in a single sample, according to the company.
by Elizabeth Tolchin As part of a massive genetics-based infertility study, researchers from the Whitehead Institute will examine the prevalence for deletions in a specific region of the Y-chromosome from over 20,000 male DNA samples provided by Genomics Collaborative Inc. (GCI).
by Elizabeth Tolchin Pfizer Inc. shared its approach to pharmacogenomics and how it is applied to their drug discovery pipeline, this week at PharmaDiscovery2004, held in New York's Jacob Javits Convention Center.
by Elizabeth Tolchin A not so new tool for DNA sequence workflow automation is getting interest from pharmaceutical companies large and small. Geospiza Inc. announced two successful rollouts of the Finch Sequencing Center this week.
by Elizabeth Tolchin Best practices for using ADME data and in vitro/in situ models was the focus of one talk today given by an Aventis scientist at the Interphex 2004 Conference and Exposition, held in New York's Jacob Javits Convention Center.